Trial Profile
A study evaluating pharmacokinetics and immunogenicity of rituximab biosimilar compared to reference rituximab in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jul 2017
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Autoimmune disorders; Cancer
- Focus Pharmacodynamics
- 28 Jul 2017 New trial record
- 27 Jun 2017 Results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics